Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

The rising prevalence of obesity has prompted the development of effective weight loss treatments. Several peptide hormones have a key role in appetite regulation and metabolism, but the discovery ...

Showing up to your laptop having to dream up every LinkedIn post from scratch is not the plan. Here’s the new plan: Follow a system to post consistently and watch the leads and opportunities ...